Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 49, 2015, Pages 15084-15089

  Zhang, Hai Nan ^a,b,c   Yang, Lina ^a   Ling, Jian Ya ^d   Czajkowsky, Daniel M ^c   Wang, Jing Fang ^a   Zhang, Xiao Wei ^e   Zhou, Yi Ming ^f   Ge, Feng ^g   Yang, Ming Kun ^g   Xiong, Qian ^g   Guo, Shu Juan ^a   Le, Huang Ying ^a   Wu, Song Fang ^a   Yan, Wei ^a   Liu, Bingya ^e   Zhu, Heng ^h   Chen, Zhu ^a,e,i   Tao, Sheng Ce ^a,b,c,i  

^a Chinese National Human Genome Center at Shanghai   (China)

^b School of Medicine   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d SHANDONG UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f NATIONAL ENGINEERING RESEARCH CENTER FOR BEIJING BIOCHIP TECHNOLOGY   (China)

^g INSTITUTE OF HYDROBIOLOGY   (China)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NONE   (China)

Author keywords

Arsenic trioxide; Glycolysis; Hexokinase 2I; Human proteome microarray

Indexed keywords

ARSENIC; ARSENIC BINDING PROTEIN; BINDING PROTEIN; GLYCOLYTIC ENZYME; HEXOKINASE; HEXOKINASE 2; UNCLASSIFIED DRUG; ARSENIC TRIOXIDE; CARRIER PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PROTEOME;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME INHIBITION; GLYCOLYSIS; HUMAN; METABOLOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; BIOLOGY; DRUG EFFECTS; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; APOPTOSIS; ARSENIC; ARSENICALS; CARRIER PROTEINS; COMPUTATIONAL BIOLOGY; GLYCOLYSIS; HEXOKINASE; HUMANS; METABOLOMICS; MOLECULAR SEQUENCE DATA; OXIDES; PROTEOME;

EID: 84949239036     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1521316112     Document Type: Article

References (32)

1. Chen S-J, et al. (2011) From an old remedy to a magic bullet: Molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 117(24): 6425-6437.
2. Shen Y, et al. (2015) Mutations of epigenetic modifier genes as a poor prognostic factor in acute promyelocytic leukemia under treatment with all-trans retinoic acid and arsenic trioxide. E Bio Medicine 2(6):563-571.
3. Mao JH, et al. (2010) As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci USA 107(50): 21683-21688.
4. Berenson JR, et al. (2006) Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: A prospective, multicentre, phase II, single-arm study. Br J Haematol 135(2): 174-183.
5. Zheng WL, et al. (2008) Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. Leuk Res 32(2):251-254.
6. Chang JE, et al. (2009) Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: A Wisconsin Oncology Network study. Hematol Oncol 27(1):11-16.
7. Liu Q, et al. (2010) The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics 3:37.
8. Ong PS, Chan SY, Ho PC (2012) Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As(2)O(3) and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR. Eur J Pharm Sci 45(3):367-378.
9. Ge F, et al. (2009) Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J Proteome Res 8(6):3006-3019.
10. Zhang X, et al. (2007) Identification of arsenic-binding proteins in human breast cancer cells. Cancer Lett 255(1):95-106.
11. Jeong JS, et al. (2012) Rapid identification of monospecific monoclonal antibodies using a human proteome microarray. Mol Cell Proteomics 11(6):016253.
12. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
13. Zhang XW, et al. (2010) Arsenic trioxide controls the fate of the PML-RARalpha on-coprotein by directly binding PML. Science 328(5975):240-243.
14. Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57.
15. Szklarczyk D, et al. (2011) The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39(Database is-sue):D561-D568.
16. Bhattacharjee H, Rosen BP (1996) Spatial proximity of Cys113, Cys172, and Cys422 in the metalloactivation domain of the ArsA ATPase. J Biol Chem 271(40):24465-24470.
17. Bailey TL, et al. (2009) MEME SUITE: Tools for motif discovery and searching. Nucleic Acids Res 37(Web Server issue):W202-208.
18. Vilensky JA, Redman K (2003) British anti-Lewisite (dimercaprol): An amazing history. Ann Emerg Med 41(3):378-383.
19. Li Y, et al. (2009) Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett 284(2):208-215.
20. Berg JM (1993) Zinc-finger proteins. Curr Opin Struct Biol 3(1):11-16.
21. Low WK, et al. (2005) Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol Cell 20(5):709-722.
22. Pirmoradian M, et al. (2013) Rapid and deep human proteome analysis by single-dimension shotgun proteomics. Mol Cell Proteomics 12(11):3330-3338.
23. Beardmore VA, et al. (2005) Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol 25(23):10454-10464.
24. Nakagawa T, Lomb DJ, Haigis MC, Guarente L (2009) SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 137(3):560-570.
25. Du J, et al. (2011) Sirt5 is a NAD-dependent protein lysine demalonylase and de-succinylase. Science 334(6057):806-809.
26. Zhou X, et al. (2011) Arsenite interacts selectively with zinc finger proteins containing C3H1 or C4 motifs. J Biol Chem 286(26):22855-22863.
27. Pan X, et al. (2010) Trivalent arsenic inhibits the functions of chaperonin complex. Genetics 186(2):725-734.
28. Zheng PZ, et al. (2005) Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA 102(21):7653-7658.
29. Krasnov GS, Dmitriev AA, Lakunina VA, Kirpiy AA, Kudryavtseva AV (2013) Targeting VDAC-bound hexokinase II: A promising approach for concomitant anti-cancer therapy. Expert Opin Ther Targets 17(10):1221-1233.
30. Laity JH, Lee BM, Wright PE (2001) Zinc finger proteins: New insights into structural and functional diversity. Curr Opin Struct Biol 11(1):39-46.
31. Bader GD, Hogue CW (2003) An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 4:2.
32. Shannon P, et al. (2003) Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498-2504.